"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 2 | 4 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 2 | 3 | 5 |
| 2001 | 0 | 4 | 4 |
| 2002 | 3 | 2 | 5 |
| 2003 | 1 | 5 | 6 |
| 2005 | 1 | 4 | 5 |
| 2006 | 0 | 4 | 4 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 6 | 7 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 8 | 12 |
| 2012 | 4 | 3 | 7 |
| 2013 | 5 | 2 | 7 |
| 2014 | 2 | 4 | 6 |
| 2015 | 5 | 5 | 10 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 5 | 7 | 12 |
| 2021 | 10 | 15 | 25 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Mild Primary or Breakthrough SARS-CoV-2 Infection Promotes Autoantibody Production in Individuals with and without Neuro-PASC. Immunohorizons. 2024 Aug 01; 8(8):577-585.
-
A proteome-wide analysis unveils a core Epstein-Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations. Int J Cancer. 2024 Oct 15; 155(8):1476-1486.
-
Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity. Nat Commun. 2024 May 16; 15(1):4177.
-
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India. Sci Rep. 2024 03 08; 14(1):5758.
-
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India. Sci Rep. 2024 01 24; 14(1):2091.
-
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
-
OPTN required SARS-CoV-2 lower respiratory testing for lung donors: Striking the balance. Transpl Infect Dis. 2023 06; 25(3):e14048.
-
Multisystem Inflammatory Syndrome in Children. Pediatr Ann. 2023 Mar; 52(3):e114-e121.
-
Pre-existing immunity modulates responses to mRNA boosters. Cell Rep. 2023 03 28; 42(3):112167.
-
Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clin Infect Dis. 2023 02 08; 76(3):e439-e449.